DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 100.15 EUR -0.1% Market Closed
Market Cap: 5.6B EUR
Have any thoughts about
DiaSorin SpA?
Write Note

Gross Margin
DiaSorin SpA

65%
Current
66%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
65%
=
Gross Profit
940.4m
/
Revenue
1.4B

Gross Margin Across Competitors

Country IT
Market Cap 5.3B EUR
Gross Margin
65%
Country US
Market Cap 198.3B USD
Gross Margin
56%
Country US
Market Cap 189.1B USD
Gross Margin
67%
Country US
Market Cap 140.4B USD
Gross Margin
64%
Country US
Market Cap 132.3B USD
Gross Margin
69%
Country IE
Market Cap 104.2B USD
Gross Margin
65%
Country US
Market Cap 65.2B USD
Gross Margin
45%
Country DE
Market Cap 58.1B EUR
Gross Margin
38%
Country US
Market Cap 44.1B USD
Gross Margin
79%
Country CN
Market Cap 309.1B CNY
Gross Margin
64%
Country US
Market Cap 36.2B USD
Gross Margin
41%
No Stocks Found

DiaSorin SpA
Glance View

Market Cap
5.3B EUR
Industry
Health Care

In the heart of the global healthcare landscape, DiaSorin SpA stands as a testament to innovation and precision in the field of biotechnology. Founded in 1968 in Italy, the company built its reputation on developing and producing diagnostic tests that help identify and monitor diseases. With a primary focus on immunodiagnostic and molecular diagnostic products, DiaSorin excels in creating high-quality, reliable solutions that clinicians and labs around the world depend on. Their product portfolio ranges widely, covering infectious diseases, oncology, endocrinology, and more. By leveraging cutting-edge research and development processes, DiaSorin not only prioritizes accuracy and efficiency in its testing solutions but also adapts to the ever-evolving demands of the medical world, cementing its role as a leader in diagnostic innovation. From a business perspective, DiaSorin's revenue streams are deeply intertwined with its prowess in developing proprietary testing technologies, including both instruments and consumables. The company operates with a dual-channel business model where it sells diagnostic machines to laboratories, hospitals, and clinics while simultaneously providing the reagents and kits necessary for these machines' continuous operation. This approach ensures not only a sale of sophisticated equipment but also a recurring revenue stream from the consumables needed for diagnostics. With a strategic emphasis on research and partnerships, DiaSorin has expanded its reach globally, ensuring its products meet diverse regional healthcare requirements. Through a combination of robust product offerings and strategic global expansion, DiaSorin continues to thrive and maintain its position as a pivotal contributor to the field of diagnostic medicine.

DIA Intrinsic Value
94.73 EUR
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
65%
=
Gross Profit
940.4m
/
Revenue
1.4B
What is the Gross Margin of DiaSorin SpA?

Based on DiaSorin SpA's most recent financial statements, the company has Gross Margin of 65%.